The company asserted that it has published as many as 9 research studies on the safety and efficacy of Covaxin in five reputed peer-reviewed journals in a span of 12 months.
Bharat Biotech's US partner for Covaxin Ocugen Thursday said it will pursue full approval through a Biologics License Application, which may delay the vaccine launch in the country.
Bharat Biotech’s statement comes at a time when the country is facing a shortage of Covid vaccines, leading to disruptions in the nationwide inoculation programme.
Duration of the emergency use listing process depends on the quality of the data submitted by the vaccine manufacturer and on those data meeting WHO criteria, according to the agency.
The trials would be on children aged 2-18 years for which Bharat Biotech may get the licence in the third quarter of this year, a FICCI Ladies Organisation press release Sunday said.
Team collected blood samples of patients who had recovered from Covid along with those who had been vaccinated with Covaxin. But experts say lab tests aren’t enough.
Citing a study published in a peer-reviewed medical journal, Bharat Biotech said noted that vaccination with Covaxin produced neutralising titers against all key emerging variants.
That the Modi government would actually dismantle the architecture of one of the UPA era’s most significant rural welfare programmes, and remove MK Gandhi’s name, took the Opposition by surprise.
It is argued that India-Israel ties are moving from buyer–seller dynamic to one focused on joint development & manufacturing partnership, a shift 'more durable' than traditional arms sales.
If Pathaan gave both conservatives and liberals room to hide, Dhurandhar extends no such courtesy. Aditya Dhar ripped open that tent of hypocrisy and turned the knife.
COMMENTS